AstraZeneca's Top 10 Medicines by Sales in Q2 '24
AstraZeneca's Strategic Q2 2024 Growth and Market Position
AstraZeneca demonstrated strong financial performance in Q2 2024, with total revenue of $12.938 billion, up 13% year-over-year as reported and 17% at constant exchange rates. For the first half of 2024, total revenue rose 15% as reported and 18% at constant exchange rates. This growth supported the company's increase in its full-year revenue and core earnings guidance. [Q2 results]
Oncology: The Cornerstone of AstraZeneca's Success
AstraZeneca's oncology segment stands as its largest revenue contributor, accounting for roughly 41% of Q2 2024 total revenue. This segment has been a primary growth driver for the company, with quarterly revenue of $5.331 billion, up 15% as reported and 19% at constant exchange rates. [Therapy-area results]
Among the noteworthy developments in this area, Enhertu, AstraZeneca's leading antibody-drug conjugate (ADC), has been a standout performer. AstraZeneca’s recognized total revenue for Enhertu rose 46% as reported (49% at constant exchange rates) to $472 million in Q2 2024; this is distinct from combined sales recorded by AstraZeneca and Daiichi Sankyo. On April 5, 2024, the FDA granted accelerated approval for adults with unresectable or metastatic HER2-positive (IHC 3+) solid tumors after prior systemic treatment when no satisfactory alternative remained. This was a tumor-agnostic indication, with eligibility defined by HER2 expression and treatment history. [FDA approval]
Patent Protection and Market Exclusivity
Enhertu's U.S. patent protection extends beyond the Q2 2024 reporting period: AstraZeneca's 2023 patent supplement listed expiry dates of 2033 and 2035. These are patent dates, not guaranteed market-exclusivity or biosimilar-launch dates. Patent challenges, additional protections and agreements permitting earlier entry can affect the competitive timeline. [Patent disclosures]
Navigating Regulatory Challenges
However, Enhertu's journey has not been without its challenges. In July 2024, NICE recommended against its use for HER2-low metastatic or unresectable breast cancer in adults after chemotherapy: its estimated cost effectiveness exceeded NICE's acceptable range, even after adjustments for severity and other benefits. This was an NHS reimbursement decision, not a refusal of marketing authorization. Separately, NICE's 2023 guidance recommended managed access for HER2-positive unresectable or metastatic breast cancer after at least one anti-HER2 treatment, subject to the access agreement. [HER2-low guidance] [HER2-positive guidance]
Tagrisso: Advancing Lung Cancer Treatment
Beyond Enhertu, Tagrisso continues to advance AstraZeneca's oncology portfolio with data from the Phase 3 LAURA trial presented at ASCO in June 2024. In unresectable stage III EGFR-mutated NSCLC after chemoradiotherapy, median progression-free survival was 39.1 months with Tagrisso versus 5.6 months with placebo. Overall survival data were immature at that analysis. Subsequent update: the FDA approved Tagrisso for this setting on September 25, 2024, for adults without progression during or after platinum-based chemoradiation whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. In March 2025, the sponsor reported an updated overall-survival hazard ratio of 0.67 (95% CI 0.40–1.14) at 31% maturity; this did not establish a statistically significant survival benefit, and final follow-up remained planned. [FDA decision] [March 2025 results]
Looking Forward
AstraZeneca's strategic focus on oncology, underscored by significant investments in innovative therapies like Enhertu and Tagrisso, has solidified its position as a leader in the BioPharma industry. Despite facing regulatory hurdles, the company's commitment to pushing the boundaries of cancer treatment remains central to its growth strategy.
As AstraZeneca navigates the complexities of global healthcare markets, its ability to innovate and adapt will be key to sustaining its upward trajectory and delivering value to both patients and investors.